Can a simple blood test spot cancer early? 25,000 volunteers help find out
NCT ID NCT06589310
First seen Jun 26, 2026 · Last updated Sep 11, 2026 · Updated 2 times
Summary
This registry study is testing a blood test designed to detect multiple types of cancer early by looking for DNA and protein changes linked to cancer. Researchers will follow 25,000 people aged 50 to 80 who take the test and any follow-up imaging. The goal is to see how well the test works in real-world settings and whether it helps catch cancer sooner.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Exact Sciences Multicancer Early Detection (MCED) blood test
- What this could lead to
- If successful, this could show that a simple blood test can catch several types of cancer early, potentially improving survival rates.
- What could go wrong
- This is an observational registry, not a controlled trial. The test may produce false positives or miss some cancers, and results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 25,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2024
- Expected to finish
-
Jan 2031
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Cohort will consist of particpants who have scheduled appointments with their primary health care provider at the participating clinics.
- Ages
-
50 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participant age at time of consent is between 50 and 80 years * Agree to receive the Exact Sciences MCED test and follow-up imaging * Willing and able to provide informed consent * Access to a suitable technology and willing to complete surveys electronically Exclusion Criteria: * Any invasive tumor (excluding non-melanoma skin cancers) or hematological malignancy in the previous three years or current suspicion of cancer and/or in active treatment (e.g., chemotherapy, radiation therapy, immunotherapy, and/or surgery
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Baylor Scott & White Health
RECRUITINGDallas, Texas, 75246, United States
-
Endeavor Health
RECRUITINGEvanston, Illinois, 60201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Two-Drug combo aims to stall advanced breast cancer
- Blood thinner flush could boost tumor biopsy success
- Could a frailty score predict which older cancer patients survive intensive care?